Literature DB >> 20528957

A genome-wide association study of bipolar disorder and comorbid migraine.

K J Oedegaard1, T A Greenwood, S Johansson, K K Jacobsen, A Halmoy, O B Fasmer, H S Akiskal, J Haavik, J R Kelsoe.   

Abstract

Both migraine and bipolar affective disorder (BPAD) are complex phenotypes with significant genetic and nongenetic components. Epidemiological and clinical studies have showed a high degree of comorbidity between migraine and BPAD, and overlapping regions of linkage have been shown in numerous genome-wide linkage studies. To identify susceptibility factors for the BPAD/migraine phenotype, we conducted a genome-wide association study (GWAS) in 1001 cases with bipolar disorder collected through the NIMH Genetics Initiative for Bipolar Disorder and genotyped at 1 m single-nucleotide polymorphisms (SNPs) as part of the Genetic Association Information Network (GAIN). We compared BPAD patients without any headache (n = 699) with BPAD patients with doctor diagnosed migraine (n = 56). The strongest evidence for association was found for several SNPs in a 317-kb region encompassing the uncharacterized geneKIAA0564 {e.g. rs9566845 [OR = 4.98 (95% CI: 2.6-9.48), P = 7.7 × 10(-8)] and rs9566867 (P = 8.2 × 10(-8))}. Although the level of significance was significantly reduced when using the Fisher's exact test (as a result of the low count of cases with migraine), rs9566845 P = 1.4 × 10(-5) and rs9566867 P = 1.5 × 10(-5), this region remained the most prominent finding. Furthermore, marker rs9566845 was genotyped and found associated with migraine in an independent Norwegian sample of adult attention deficit hyperactivity disorder (ADHD) patients with and without comorbid migraine (n = 131 and n = 324, respectively), OR = 2.42 (1.18-4.97), P = 0.013. This is the first GWAS examining patients with bipolar disorder and comorbid migraine. These data suggest that genetic variants in the KIAA0564 gene region may predispose to migraine headaches in subgroups of patients with both BPAD and ADHD.
© 2010 The Authors. Genes, Brain and Behavior © 2010 Blackwell Publishing Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20528957      PMCID: PMC2970709          DOI: 10.1111/j.1601-183X.2010.00601.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  37 in total

Review 1.  Family, twin, and adoption studies of bipolar disorder.

Authors:  Jordan W Smoller; Christine T Finn
Journal:  Am J Med Genet C Semin Med Genet       Date:  2003-11-15       Impact factor: 3.908

2.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

3.  A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group.

Authors:  C L Bowden; J R Calabrese; S L McElroy; L Gyulai; A Wassef; F Petty; H G Pope; J C Chou; P E Keck; L J Rhodes; A C Swann; R M Hirschfeld; P J Wozniak
Journal:  Arch Gen Psychiatry       Date:  2000-05

4.  Screening for bipolar disorder in the community.

Authors:  Robert M A Hirschfeld; Joseph R Calabrese; Myrna M Weissman; Michael Reed; Marilyn A Davies; Mark A Frye; Paul E Keck; Lydia Lewis; Susan L McElroy; James P McNulty; Karen D Wagner
Journal:  J Clin Psychiatry       Date:  2003-01       Impact factor: 4.384

5.  A genome screen of 13 bipolar affective disorder pedigrees provides evidence for susceptibility loci on chromosome 3 as well as chromosomes 9, 13 and 19.

Authors:  R F Badenhop; M J Moses; A Scimone; P B Mitchell; K R Ewen-White; A Rosso; J A Donald; L J Adams; P R Schofield
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

6.  Prevalence, clinical correlates, and treatment of migraine in bipolar disorder.

Authors:  Nancy C P Low; Guillaume Galbaud Du Fort; Pablo Cervantes
Journal:  Headache       Date:  2003-10       Impact factor: 5.887

7.  Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative.

Authors:  J I Nurnberger; M C Blehar; C A Kaufmann; C York-Cooler; S G Simpson; J Harkavy-Friedman; J B Severe; D Malaspina; T Reich
Journal:  Arch Gen Psychiatry       Date:  1994-11

8.  A genome-wide linkage study of bipolar disorder and co-morbid migraine: replication of migraine linkage on chromosome 4q24, and suggestion of an overlapping susceptibility region for both disorders on chromosome 20p11.

Authors:  K J Oedegaard; T A Greenwood; A Lunde; O B Fasmer; H S Akiskal; J R Kelsoe
Journal:  J Affect Disord       Date:  2009-10-12       Impact factor: 4.839

9.  Migraine and concomitant symptoms among 8167 adult twin pairs.

Authors:  M L Honkasalo; J Kaprio; T Winter; K Heikkilä; M Sillanpää; M Koskenvuo
Journal:  Headache       Date:  1995-02       Impact factor: 5.887

10.  Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2.

Authors:  Maurizio De Fusco; Roberto Marconi; Laura Silvestri; Luigia Atorino; Luca Rampoldi; Letterio Morgante; Andrea Ballabio; Paolo Aridon; Giorgio Casari
Journal:  Nat Genet       Date:  2003-01-21       Impact factor: 38.330

View more
  17 in total

1.  Bipolar disorder and chronic migraine: an open problem.

Authors:  Ottavio Di Marco; Stefania Di Mauro
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

2.  Research resource: identification of novel coregulators specific for thyroid hormone receptor-β2.

Authors:  Johnnie B Hahm; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2013-04-04

Review 3.  Genetic basis of pain variability: recent advances.

Authors:  Erin E Young; William R Lariviere; Inna Belfer
Journal:  J Med Genet       Date:  2011-11-05       Impact factor: 6.318

4.  Parental and comorbid migraine in individuals with bipolar disorder: A nationwide register study.

Authors:  Dan Sucksdorff; Alan S Brown; Roshan Chudal; Markus Heinimaa; Auli Suominen; Andre Sourander
Journal:  J Affect Disord       Date:  2016-07-19       Impact factor: 4.839

5.  Von Willebrand factor A domain-containing protein 8 (VWA8) localizes to the matrix side of the inner mitochondrial membrane.

Authors:  Moulun Luo; Wuqiong Ma; Zoe Sand; Jean Finlayson; Tian Wang; Roberta Diaz Brinton; Wayne T Willis; Lawrence J Mandarino
Journal:  Biochem Biophys Res Commun       Date:  2019-10-17       Impact factor: 3.575

6.  Genome wide association study identifies variants in NBEA associated with migraine in bipolar disorder.

Authors:  Kaya K Jacobsen; Caroline M Nievergelt; Tetyana Zayats; Tiffany A Greenwood; Verneri Anttila; Hagop S Akiskal; Jan Haavik; Ole Bernt Fasmer; John R Kelsoe; Stefan Johansson; Ketil J Oedegaard
Journal:  J Affect Disord       Date:  2014-10-12       Impact factor: 4.839

7.  Characterization of the novel protein KIAA0564 (Von Willebrand Domain-containing Protein 8).

Authors:  Moulun Luo; April E Mengos; Wuqiong Ma; Jean Finlayson; Rocio Zapata Bustos; Yuan Xiao Zhu; Chang-Xin Shi; Tianna M Stubblefield; Wayne T Willis; Lawrence J Mandarino
Journal:  Biochem Biophys Res Commun       Date:  2017-04-13       Impact factor: 3.575

8.  A bivariate mann-whitney approach for unraveling genetic variants and interactions contributing to comorbidity.

Authors:  Yalu Wen; Daniel J Schaid; Qing Lu
Journal:  Genet Epidemiol       Date:  2013-01-17       Impact factor: 2.135

9.  Bipolar disorder with comorbid binge eating history: a genome-wide association study implicates APOB.

Authors:  Stacey J Winham; Alfredo B Cuellar-Barboza; Susan L McElroy; Alfredo Oliveros; Scott Crow; Colin L Colby; Doo-Sup Choi; Mohit Chauhan; Mark A Frye; Joanna M Biernacka
Journal:  J Affect Disord       Date:  2014-04-19       Impact factor: 4.839

Review 10.  Use of next generation sequencing technologies in research and beyond: are participants with mental health disorders fully protected?

Authors:  Iris Jaitovich Groisman; Ghislaine Mathieu; Beatrice Godard
Journal:  BMC Med Ethics       Date:  2012-12-20       Impact factor: 2.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.